Drug Profile
XL 888
Alternative Names: EXEL-4888; Heat Shock Protein 90 Inhibitor XL888; Hsp90 Inhibitor XL888; XL888Latest Information Update: 02 Feb 2023
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Emory University; Exelixis; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme
- Class Antineoplastics; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Gastrointestinal cancer
- Phase I Malignant melanoma
Most Recent Events
- 02 Feb 2023 XL 888 is still in phase I trials for Malignant melanoma in the US (NCT01657591)
- 02 Feb 2023 Exelixis completes a phase I trial for Malignant melanoma (Late-stage disease, Inoperable/Unresectable, Combination therapy) in USA (PO) (NCT01657591)
- 10 Jun 2021 Merck in collaboration with Exelixis and Emory University completes a phase I trial in Gastrointestinal cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT03095781)